RSK/AKT/S6K抑制剂TAS0612联合维奈克拉对多发性骨髓瘤具有强效抗骨髓瘤作用,且不受细胞遗传学异常影响
多发性骨髓瘤(MM)因细胞遗传学、遗传学和分子异常复杂异质而难以治疗。本研究基于RSK2和AKT下游效应信号分子的关键作用,探讨三重抑制剂TAS0612(靶向RSK、AKT和S6K)的抗骨髓瘤效力。TAS0612通过细胞周期阻滞和诱导凋亡抑制多种细胞遗传学背景的人骨髓瘤细胞系增殖,离体处理显著降低患者原代骨髓瘤细胞活力,并上调抑癌基因、下调Myc和mTOR相关基因;与维奈克拉(VEN)联合诱导凋亡具有协同作用,且不论t(11;14)易位状态。
要点
- TAS0612通过细胞周期阻滞和凋亡诱导抑制多发性骨髓瘤细胞增殖。
- TAS0612离体处理显著降低不同细胞遗传学特征患者原代骨髓瘤细胞活力。
- TAS0612联合维奈克拉协同诱导凋亡,不论t(11;14)易位状态。
核心结论
- TAS0612单药及联合维奈克拉是不受细胞遗传学/遗传学特征影响的MM新型强效候选治疗策略,有助于其未来临床开发。
研究设计与样本
- 研究使用多种细胞遗传学和遗传学背景的人骨髓瘤细胞系(HMCLs)及患者来源原代骨髓瘤细胞进行离体实验,评估TAS0612单药及联合维奈克拉的抗骨髓瘤活性。
主要发现
- TAS0612通过细胞周期阻滞和诱导凋亡在多种细胞遗传学和遗传学背景的HMCLs中发挥抗增殖作用。
- 离体TAS0612处理显著降低不同细胞遗传学特征患者原代骨髓瘤细胞的活力。
- TAS0612同时上调若干抑癌基因,根据MMRF CoMMpass数据调节预后基因,并下调一系列Myc和mTOR相关基因。
- TAS0612联合维奈克拉在HMCLs中协同诱导凋亡,不论t(11;14)易位状态。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) remains a difficult-to-treat disease even with the latest therapeutic advances due to the complex, overlapping, and heterogeneous cytogenetic, genetic, and molecular abnormalities. To address this challenging problem, we previously identified the universal and critical roles of RSK2 and AKT, the effector signaling molecules downstream of PDPK1, regardless of cytogenetic and genetic profiles. Based on this, in this study, we investigated the anti-myeloma potency of TAS0612, a triple inhibitor against RSK, including RSK2, AKT, and S6K. Treatment with TAS0612 exerted the anti-proliferative effect via cell cycle blockade and the induction of apoptosis in human myeloma-derived cell lines (HMCLs) with diverse cytogenetic and genetic profiles. Ex vivo treatment with TAS0612 also significantly reduced the viability of patient-derived primary myeloma cells with diverse cytogenetic profiles. TAS0612 simultaneously caused the upregulation of several tumor suppressor genes, modulated prognostic genes according to the MMRF CoMMpass data, and downregulated a series of Myc- and mTOR-related genes. Moreover, the combination of TAS0612 with venetoclax (VEN) showed the synergy in inducing apoptosis in HMCLs irrespective of the t(11;14) translocation status. TAS0612 alone and combined with VEN are new potent candidate therapeutic strategies for MM, regardless of cytogenetic/genetic profiles, facilitating its future clinical development.
引用
- Okamoto H, Mizutani S, Tsukamoto T, et al. Robust anti-myeloma effect of TAS0612, an RSK/AKT/S6K inhibitor, with venetoclax regardless of cytogenetic abnormalities. Leukemia. 2024. PMID: 39438587. doi:10.1038/s41375-024-02439-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。